EVO
Evotec SE NASDAQ Listed Feb 5, 2004$2.56
-1.92%
vs $2.61
Mkt Cap $909.2M
52w Low $2.31
12.3% of range
52w High $4.34
50d MA $2.94
200d MA $3.24
P/E (TTM)
-9.1x
EV/EBITDA
—
P/B
1.1x
Debt/Equity
0.6x
ROE
—
P/FCF
-11.5x
RSI (14)
26.20
ATR (14)
$0.07
Beta
1.24
50d MA
$2.94
200d MA
$3.24
Avg Volume
45.5K
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Essener Bogen 7 · Hamburg 22419 · DE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | TNS | 0.21 | 0.06 | -73.9% | 2.69 | -2.6% | -2.6% | +0.4% | +5.7% | +12.2% | +2.9% | — |
| Nov 5, 2025 | TNS | -0.14 | -0.14 | -1.4% | 3.35 | +0.0% | -1.2% | -6.9% | -2.9% | -0.7% | +5.7% | — |
| Aug 13, 2025 | TNS | -0.18 | -0.14 | +19.9% | 3.81 | +1.0% | +0.3% | -1.6% | -2.1% | -1.9% | -1.1% | — |
| May 6, 2025 | TNS | -0.11 | -0.20 | -77.3% | 4.05 | +2.0% | +3.0% | -6.2% | +10.0% | -3.0% | +0.7% | — |
| Apr 17, 2025 | TNS | 0.02 | -0.12 | -768.4% | 3.60 | -3.6% | -0.6% | +10.9% | +3.0% | +2.9% | +0.2% | — |
| Nov 6, 2024 | TNS | -0.08 | -0.12 | -50.0% | 3.87 | +9.6% | +9.8% | -2.8% | +17.9% | -8.8% | +2.5% | — |
| Aug 14, 2024 | TNS | -0.09 | -0.29 | -222.2% | 3.31 | +0.3% | -3.6% | +2.2% | -1.5% | -0.3% | -3.1% | — |
| May 22, 2024 | TNS | -0.03 | -0.05 | -49.6% | 5.17 | -3.7% | -4.6% | -3.2% | +1.9% | -5.8% | -1.3% | — |
| Feb 26, 2024 | TNS | -0.03 | -0.05 | -66.7% | 7.63 | +0.7% | +0.3% | -2.1% | -1.2% | +1.8% | -4.4% | — |
| Nov 8, 2023 | TNS | -0.05 | -0.12 | -140.0% | 9.27 | +5.1% | +4.0% | -3.2% | +0.6% | +7.2% | -0.5% | — |
| Aug 29, 2023 | TNS | -0.04 | -0.04 | -10.8% | 12.09 | -1.8% | -0.6% | -1.5% | -0.3% | -2.9% | +1.1% | — |
| May 12, 2023 | TNS | 0.10 | -0.08 | -180.0% | 10.19 | +5.2% | +6.0% | +2.6% | -3.1% | -3.0% | +2.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.81 | $3.85 | +1.0% | +0.3% | -1.6% | -2.1% | -1.9% | -1.1% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.87 | $4.24 | +9.6% | +9.8% | -2.8% | +17.9% | -8.8% | +2.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.31 | $3.32 | +0.3% | -3.6% | +2.2% | -1.5% | -0.3% | -3.1% |
| May 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.17 | $4.98 | -3.7% | -4.6% | -3.2% | +1.9% | -5.8% | -1.3% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.23 | $5.11 | -2.3% | -2.5% | -1.6% | +3.6% | -0.2% | +1.2% |
| Aug 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.02 | $11.74 | -2.3% | -1.5% | -0.3% | -2.9% | +1.1% | -1.3% |
| Jul 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.91 | $11.97 | +0.5% | +1.3% | +1.4% | +0.7% | +0.1% | +3.5% |
| Jun 23 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $11.21 | $11.45 | +2.1% | +3.9% | -5.2% | +1.0% | +2.0% | -1.8% |
| Jun 16 | BofA Securities | Downgrade | Buy → Neutral | — | $11.85 | $11.77 | -0.7% | -1.6% | -2.5% | +0.4% | -1.8% | +3.9% |
| Jun 8 | Citigroup | Upgrade | Neutral → Buy | — | $11.26 | $12.45 | +10.6% | +10.8% | -2.2% | +1.6% | -1.8% | -3.4% |
| Apr 4 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $10.71 | $10.81 | +0.9% | +1.4% | -0.3% | +3.3% | -1.9% | -6.2% |
| Mar 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.14 | $10.45 | +3.1% | +1.2% | +1.9% | +0.0% | +2.5% | +1.4% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.34 | $10.14 | -1.9% | -1.7% | -3.1% | -1.0% | +1.0% | +6.9% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.38 | $8.49 | +1.3% | +0.5% | +1.0% | -0.1% | -0.5% | -4.6% |
| Nov 16 | Deutsche Bank | Downgrade | Buy → Hold | — | $9.25 | $9.01 | -2.6% | -5.3% | +0.5% | -4.0% | -2.1% | -1.0% |
| Aug 10 | Morgan Stanley | Downgrade | Overweight → Underweight | — | $14.13 | $12.65 | -10.5% | -7.1% | +0.1% | +6.3% | -1.2% | -0.7% |
| Nov 29 | TD Cowen | Maintains | Outperform → Outperform | — | $23.73 | $22.75 | -4.1% | -4.2% | +3.6% | -2.8% | +0.9% | -2.6% |
| Aug 15 | Stifel | Downgrade | Buy → Hold | — | $2.44 | $2.42 | -0.8% | -0.4% | +2.9% | -2.0% | +0.0% | +0.0% |
| Aug 14 | Stifel | Downgrade | Buy → Hold | — | — | — | — | — | — | — | — | — |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 519,180 | $2M | Reduced | Dec 2025 |
| 2 | Abc Arbitrage Sa | 509,050 | $1M | Reduced | Mar 2026 |
| 3 | Jane Street Group, Llc | 183,286 | $565K | New | Dec 2025 |
| 4 | Millennium Management | 99,568 | $249K | Reduced | Mar 2026 |
| 5 | Citadel Advisors Llc | 87,180 | $218K | Added | Mar 2026 |
| 6 | Pathstone Holdings, Llc | 34,127 | $85K | New | Mar 2026 |
| 7 | Quadrant Capital Group Llc | 1,096 | $50K | Reduced | Mar 2026 |
| 8 | Vanguard Personalized Indexing Management, Llc | 20,115 | $50K | Added | Mar 2026 |
| 9 | Axq Capital, Lp | 15,354 | $38K | New | Mar 2026 |
| 10 | Bnp Paribas Financial Markets | 15,279 | $38K | Reduced | Mar 2026 |
| 11 | Marshall Wace, Llp | 15,189 | $38K | Added | Mar 2026 |
| 12 | Apollon Wealth Management, Llc | 11,168 | $28K | New | Mar 2026 |
| 13 | Hrt Financial Lp | 10,510 | $26K | Reduced | Mar 2026 |
| 14 | Rockefeller Capital Management L.p. | 10,219 | $26K | Added | Mar 2026 |
| 15 | Point72 Asset Management | 10,043 | $25K | Reduced | Mar 2026 |
| 16 | Umb Bank, N.a. | 7,192 | $18K | Reduced | Mar 2026 |
| 17 | Ubs Group Ag | 1,501 | $4K | New | Mar 2026 |
| 18 | Smartleaf Asset Management Llc | 1,326 | $3K | — | Mar 2026 |
| 19 | Private Trust Co Na | 490 | $1K | New | Mar 2026 |
| 20 | Leo H. Evart, Inc. | 456 | $1K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$909.2M
Enterprise Value
$627.8M
P/E (TTM)
-9.14x
Forward P/E
—
PEG Ratio
0.19x
P/B
1.12x
P/S
1.20x
P/FCF
-11.55x
EV/EBITDA
—
Shares Out
355.2M
Financials (TTM)
Revenue
$757.3M
Net Income
-$99.4M
EBITDA
-$39.8M
Free Cash Flow
-$78.7M
Op Cash Flow
-$9.1M
EPS Basic
$-0.28
EPS Diluted
$-0.28
EPS Forward
$-0.24
Gross Margin
8.3%
Op Margin
-17.9%
Net Margin
-13.1%
Balance Sheet
Total Assets
$1.78B
Total Liab.
$964.6M
Total Equity
$813.4M
Cash
$476.2M
LT Debt
$194.8M
Book Value/Sh
$2.29
Debt/Equity
0.55x
Current Ratio
2.07
Quick Ratio
1.99
Returns & Growth
ROE
—
ROA
—
ROIC
-7.2%
Rev Growth YoY
-5.0%
EPS Growth YoY
+49.5%
Price Returns
2W
+12.9%
1M
-1.3%
3M
-9.7%
6M
-7.8%
12M
-22.7%
Technicals
52W High
$4.34
52W Low
$2.31
50d MA
$2.94
200d MA
$3.24
RSI (14)
26.20
ATR (14)
$0.07
Beta
1.24
Avg Volume
46K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
12
Ex-Div Date
Jan 11, 2019
Analyst Price Targets
Consensus
$7.00
High
$7.00
Low
$7.00
Median
$7.00
Data updated apr 26, 2026 10:32am
· Source: financialmodelingprep.com